But the company announced this morning that work is being halted on the drug after getting a glimpse of data from a phase 2 trial of three different doses of ASC42 to treat PBC. The results “indicated that ASC42 did not show competitiveness to new PBC drug candidates currently in development and registrational stages,” the company explained in an April 4 release.
Based on this failure, Ascletis has also decided to drop other programs involving the drug. These include testing the therapy for hepatitis B virus (HBV) as well as part of a combo treatment for MASH.
The biotech, which entered the year with cash and equivalents of 2.4 billion Chinese Yuan ($330 million), attributed today’s decision to “efforts to continue to evaluate and optimize its research and development pipeline to increase efficiency and preserve cash.”
Viking has previously accused Ascletis of stealing trade secrets to support the development of a drug candidate to rival its MASH prospect VK2809. That dispute rumbled on throughout last year, during which time Gannex continued to work toward midphase data on the molecule at the center of the row.
Part of the savings from discontinuing the various ASC42 programs will be funneled into the continued clinical development of ASC41 and ASC40 for MASH, the biotech explained in today’s release.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.